COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
Piehl F, Alping P, Virtanen S, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Mellergård J, Nilsson P, Olsson T, Salzer J, Svenningsson A, Frisell T.
Piehl F, et al. Among authors: virtanen s.
Ann Neurol. 2024 Oct;96(4):678-693. doi: 10.1002/ana.27012. Epub 2024 Jun 25.
Ann Neurol. 2024.
PMID: 38923558